Study identification

PURI

https://redirect.ema.europa.eu/resource/1000000105

EU PAS number

EUPAS1000000105

Study ID

1000000105

Official title and acronym

A propensity score-matched analysis of depersonalized 4-week data from the German Pain e-Registry on the efficacy and tolerability of quinine sulphate vs. pridinol mesylate in the prevention and treatment of painful nocturnal leg cramps (PRISCILA)

DARWIN EU® study

No

Study countries

Germany

Study description

PRISCILA is an exploratory, non-interventional, post-marketing, open-label, retrospective parallel-group, comparative 4-week two-cohort-study using depersonalized data of the German Pain e-Registry (until September 30, 2023) to assess the effectiveness of the nonbenzodiazepine antispasmodic pridinol (PRI) compared to quinine sulphate (QUI) in adult patients with advanced nocturnal leg cramps (NLC) who are deemed to be in need of prescription drugs according to the mutual / shared decision of the responsible physicians and affected patients.

The primary objective of this study was the evaluation of the 4-week responder rate in comparable patient populations of the German Pain e-Registry (GPeR) with insufficient symptom relief in response to self-medication and/or non-pharmacological countermeasures for NLC who either received a prescription for QUI or alternatively with PRI.

Secondary objectives of this study focused on the overall prevalence and severity of adverse drug reactions (ADRs), ADR- and inefficiency-related treatment discontinuations in both study cohorts.
This study used depersonalized data from the German Pain e-Registry (GPeR) which is a nation-wide, web-based pain registry developed by the Institute of Neurological Sciences (IFNAP; Nuernberg) on behalf of the German Pain League (Deutsche Schmerzliga, DSL eV) to support the German Pain Association (Deutsche Gesellschaft für Schmerzmedizin, DGS eV) and its individual members to comply with the legal requirements regarding standardized documentation in pain medicine, as well as to facilitate better pain management care for people in need of it. The GPeR provides patients and physicians with standardized, fully electronic documentation aids that can be adapted to the specifics of each individual case and that collect patient reported information on demography, history, previous and current treatment, pain characteristics and treatment response, within a daily practice setting.

Study status

Finalised
Research institutions and networks

Institutions

Contact details

Michael Ueberall

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Study is sponsored by Strathmann GmbH & Co. KG (70%) and by O.Meany-MDPM GmbH (30%).
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable